PT-141
10mgVolume Pricing
Per unit — bulk discounts applied automaticallyWholesale pricing available for approved accounts
About PT-141
Bremelanotide — a synthetic cyclic heptapeptide melanocortin receptor agonist. Derived from Melanotan II, PT-141 is studied for its selective activity at MC3R and MC4R receptors in neuroendocrine research.
Frequently Asked Questions
All Signal peptides undergo rigorous third-party testing and are guaranteed ≥99% purity. Every batch comes with a Certificate of Analysis (COA) verified through AuthentiChain's blockchain verification system.
Orders placed before 12PM EST ship same-day via cold chain logistics. Products are shipped in insulated packaging with dry ice to maintain temperature integrity. Standard delivery is 1–3 business days.
Approved accounts have access to flexible payment terms including NET 30, wire transfer, and credit card. Volume-based pricing is automatically applied at checkout based on your order quantity.
Absolutely. Contact your dedicated account manager or reach out to info@signalpeps.com with the product name and lot number. COAs are also available digitally through our AuthentiChain verification badge on each product page.
Published Study Findings on PT-141
Detailed Research & Citations
In-depth findings from peer-reviewed preclinical and clinical studies
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II, studied for its selective activity at MC3R and MC4R receptors in the central nervous system.
Central MC3R/MC4R Activation
PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus, influencing dopamine release and neuroendocrine signaling — a central mechanism of action distinct from peripherally-acting compounds.
Annals of the New York Academy of Sciences (2003)Female Sexual Dysfunction Studies
In randomized, placebo-controlled double-blind trials, bremelanotide demonstrated statistically significant improvements in desire scores and reductions in distress in premenopausal women with hypoactive sexual desire disorder (HSDD). FDA-approved as Vyleesi.
Obstetrics & Gynecology (2019)Male Erectile Function Studies
Double-blind, placebo-controlled studies demonstrated PT-141 induced erections and improved erectile function in men, including those non-responsive to PDE5 inhibitors, via its central melanocortin pathway mechanism.
Annals of the New York Academy of Sciences (2003)Safety & Tolerability Profile
Across multiple clinical trials, bremelanotide was generally well-tolerated via subcutaneous administration. Common reported effects included transient nausea, flushing, and headache. Contraindicated in uncontrolled hypertension.
Obstetrics & Gynecology (2019)View All 2 Sources
All findings above are sourced from peer-reviewed journals for educational reference. This product is for research purposes only — not for human consumption. Preclinical results may not translate to human outcomes.
Chemical Identity
How to Order
Three simple steps to access premium research peptides
Apply for an Account
Submit a quick application with your business details. Takes less than 2 minutes.
Get Approved
Our team reviews applications within 1–2 business days. You'll receive an email once approved.
Place Your Order
Browse the catalog, select quantities, and checkout. Volume pricing applies automatically.
All products are for research and laboratory purposes only. Not intended for human or animal consumption. Only qualified professionals should handle these products.
